Last updated on October 2007

Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Refractory Acute Promyelocytic Leukemia | Relapsed Acute Promyelocytic Leukemia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Patients in first or subsequent hematological or molecular relapse of APL
    Persistence of a positive PCR or no hematological complete remission (CR) after first
    line therapy
    No complete hematological remission after first line therapy
    Age over 18 years
    No upper age limit
    Informed consent of the patient

You may not be eligible for this study if the following are true:

  • Absolute QTc-interval prolonged over 460 msec before therapy (normal electrolytes, no
    other drugs prolonging the QT-interval)
    Heart failure New York Health Association grade III and IV
    Renal or hepatic failure World Health Organization grade >= III
    Pneumonia with hypoxemia
    Uncontrolled sepsis
    Pregnancy and lactation period
    Secondary malignancy, which will have major influence on the prognosis
    Expected noncompliance
    No informed consent of the patient.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.